Successful treatment of multiply relapsed lymphoma with rituximab as a single agent Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • AbstractThe treatment of non‐Hodgkin lymphoma (NHL) is an example of the successful therapy of cancer in children; the cure rate overall at approximately 80%. Unfortunately, relapsed NHL has a dismal prognosis, and the customary treatment is highly toxic chemotherapy followed by hematopoietic stem cell transplantation (HSCT). A child with relapsed T‐cell rich B‐NHL was treated with rituximab alone. This was delivered in eight doses after the recurrence of disease after high‐dose chemotherapy and allogenic HSCT that was undertaken for the first relapse. Eight years after the last dose of rituximab he remains in complete remission. Pediatr Blood Cancer. 2010;55:356–358. © 2010 Wiley–Liss, Inc.

publication date

  • August 2010